VEGFA and metastatic colorectal cancer: We have previously shown that a pro-angiogenic factor, the vascular endothelial growth factor-A (VEGF-A) which is highly produced in tumor-bearing hosts, could be involved in the accumulation of Treg and that anti-angiogenic (AA) molecules targeting the VEGF-A/VEGFR pathway could decrease Treg in a mouse model of colorectal cancer and metastatic colorectal cancer patients [2].